Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Traneurocin (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NeuroActiva

Most Recent Events

  • 19 Aug 2024 According to a Biomed Industries media release, company unveiled new data and introduced a Phase 2 Clinical Trial protocol for its innovative stroke treatment drug, NA-911 in a paper titled Associations Between Alzheimer's Disease and Stroke: Clinical Studies of NA-831 for AD and NA-911 for Stroke was presented at the Alzheimer's Association International Conference, held from July 27 to August 1, 2024, in Philadelphia, PA, USA.
  • 18 May 2023 According to a Biomed Industries media release, results from this trial were presented at the Alzheimer's Association International Conference 2022
  • 18 May 2023 According to a Biomed Industries media release, results from this trial were presented at the Alzheimer's Disease/Parkinson's Disease International Conference 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top